Loading…
Reported covered position: Chief Health Counsel for Chairman - House E&C Committee (E&C); Deputy Chief Health Counsel - E&C; Professional Staff - E&C; Health Care Policy Advisor - Senate; Deputy Director Office of Refugee Resettlement HHS; WH Office of Presidential Personnel
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Accelerating Kids’ Access to Care Act of 2025
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: LEAVITT PARTNERS, LLC
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Accelerating Kids’ Access to Care Act of 2025
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: LEAVITT PARTNERS, LLC
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ORCHARD THERAPEUTICS NORTH AMERICA via LEAVITT PARTNERS, LLC
2026 · third_quarter · Q3
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2026 · third_quarter · Q3
Source: Senate LDA
| COVID PATIENT RECOVERY ALLIANCE |
| 8 |
| 2021–2023 |
| LUNDBECK PHARMACEUTICALS, LLC | 7 | 2021–2022 |
| ORCHARD THERAPEUTICS NORTH AMERICA | 3 | 2026 |
Accelerating Kids’ Access to Care Act of 2025
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: LEAVITT PARTNERS, LLC
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Accelerating Kids’ Access to Care Act
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: LEAVITT PARTNERS, LLC
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Accelerating Kids’ Access to Care Act
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: LEAVITT PARTNERS, LLC
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Accelerating Kids’ Access to Care Act
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: LEAVITT PARTNERS, LLC
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Supporting Care for Dual Eligibles Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Supporting Care for Dual Eligibles Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Supporting Care for Dual Eligibles Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Advancing Integration in Medicare and Medicaid (AIM) Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Advancing Integration in Medicare and Medicaid (AIM) Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Advancing Integration in Medicare and Medicaid (AIM) Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Supporting States in Integrating Care Act of 2022
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Supporting States in Integrating Care Act of 2022
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Supporting States in Integrating Care Act of 2022
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Comprehensive Care for Dual Eligible Individuals Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Comprehensive Care for Dual Eligible Individuals Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Comprehensive Care for Dual Eligible Individuals Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Supporting Care for Dual Eligibles Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Supporting Care for Dual Eligibles Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Supporting Care for Dual Eligibles Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Supporting Care for Dual Eligibles Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Advancing Integration in Medicare and Medicaid (AIM) Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Supporting States in Integrating Care Act of 2022
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Supporting States in Integrating Care Act of 2022
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Supporting States in Integrating Care Act of 2022
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Supporting States in Integrating Care Act of 2022
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Comprehensive Care for Dual Eligible Individuals Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Comprehensive Care for Dual Eligible Individuals Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Comprehensive Care for Dual Eligible Individuals Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Comprehensive Care for Dual Eligible Individuals Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Supporting Care for Dual Eligibles Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Supporting Care for Dual Eligibles Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Supporting Care for Dual Eligibles Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Supporting Care for Dual Eligibles Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Supporting States in Integrating Care Act of 2022
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Supporting States in Integrating Care Act of 2022
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Supporting States in Integrating Care Act of 2022
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Supporting States in Integrating Care Act of 2022
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Comprehensive Care for Dual Eligible Individuals Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Comprehensive Care for Dual Eligible Individuals Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Comprehensive Care for Dual Eligible Individuals Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Comprehensive Care for Dual Eligible Individuals Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Supporting Care for Dual Eligibles Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
Issues related to dual eligible beneficiaries including: S.4635 - Comprehensive Care for Dual Eligible Individuals Act S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 S, 4264 Advancing Integration in Medicare and Medicaid Act S. 3630 The Supporting Care for Dual Eligibles Act
Supporting Care for Dual Eligibles Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Supporting Care for Dual Eligibles Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Supporting Care for Dual Eligibles Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Supporting States in Integrating Care Act of 2022
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Supporting States in Integrating Care Act of 2022
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Supporting States in Integrating Care Act of 2022
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
Issues related to dual eligible beneficiaries including: S.4635 - Comprehensive Care for Dual Eligible Individuals Act S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 S, 4264 Advancing Integration in Medicare and Medicaid Act S. 3630 The Supporting Care for Dual Eligibles Act
Supporting States in Integrating Care Act of 2022
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Comprehensive Care for Dual Eligible Individuals Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Comprehensive Care for Dual Eligible Individuals Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Comprehensive Care for Dual Eligible Individuals Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Comprehensive Care for Dual Eligible Individuals Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
Issues related to dual eligible beneficiaries including: S.4635 - Comprehensive Care for Dual Eligible Individuals Act S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 S, 4264 Advancing Integration in Medicare and Medicaid Act S. 3630 The Supporting Care for Dual Eligibles Act
Supporting Care for Dual Eligibles Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
Issues related to dual eligible beneficiaries including: S.4635 - Comprehensive Care for Dual Eligible Individuals Act S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 S, 4264 Advancing Integration in Medicare and Medicaid Act S. 3630 The Supporting Care for Dual Eligibles Act
Supporting Care for Dual Eligibles Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
Issues related to dual eligible beneficiaries including: S.4635 - Comprehensive Care for Dual Eligible Individuals Act S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 S, 4264 Advancing Integration in Medicare and Medicaid Act S. 3630 The Supporting Care for Dual Eligibles Act
Supporting States in Integrating Care Act of 2022
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
Issues related to dual eligible beneficiaries including: S.4635 - Comprehensive Care for Dual Eligible Individuals Act S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 S, 4264 Advancing Integration in Medicare and Medicaid Act S. 3630 The Supporting Care for Dual Eligibles Act
Supporting States in Integrating Care Act of 2022
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
Issues related to dual eligible beneficiaries including: S.4635 - Comprehensive Care for Dual Eligible Individuals Act S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 S, 4264 Advancing Integration in Medicare and Medicaid Act S. 3630 The Supporting Care for Dual Eligibles Act
Comprehensive Care for Dual Eligible Individuals Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
Issues related to dual eligible beneficiaries including: S.4635 - Comprehensive Care for Dual Eligible Individuals Act S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 S, 4264 Advancing Integration in Medicare and Medicaid Act S. 3630 The Supporting Care for Dual Eligibles Act
Comprehensive Care for Dual Eligible Individuals Act
Client: THE DUAL ELIGIBLE COALITION · Firm: LEAVITT PARTNERS, LLC
Issues related to dual eligible beneficiaries including: S.4635 - Comprehensive Care for Dual Eligible Individuals Act S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 S, 4264 Advancing Integration in Medicare and Medicaid Act S. 3630 The Supporting Care for Dual Eligibles Act
Work with Congress and the Administration to ensure Medicaid coverage of genomic sequencing for children with suspected rare diseases, genetic disorders, and undiagnosed conditions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SAVE RARE TREATMENTS TASK FORCE via LEAVITT PARTNERS, LLC
2026 · third_quarter · Q3
Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases. Reauthorization of the Pediatric Rare Disease Priority Review Voucher Program. Most Favored Nation (MFN) models and international reference pricing, including GLOBE and GUARD
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SICKLE CELL DISEASE PARTNERSHIP via LEAVITT PARTNERS, LLC
2026 · third_quarter · 3A
Sickle cell disease focused legislation, federal funding, and federal programs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
340B WORKING TABLE via LEAVITT PARTNERS, LLC
2026 · third_quarter · Q3
Improvements to the 340B drug discount program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SICKLE CELL DISEASE PARTNERSHIP via LEAVITT PARTNERS, LLC
2026 · third_quarter · Q3
Sickle cell disease focused legislation, federal funding, and federal programs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE DUAL ELIGIBLE COALITION via LEAVITT PARTNERS, LLC
2026 · third_quarter · Q3
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via LEAVITT PARTNERS, LLC
2026 · second_quarter · Q2
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2026 · second_quarter · Q2
Work with Congress and the Administration to ensure Medicaid coverage of genomic sequencing for children with suspected rare diseases, genetic disorders, and undiagnosed conditions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SAVE RARE TREATMENTS TASK FORCE via LEAVITT PARTNERS, LLC
2026 · second_quarter · Q2
Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases. Reauthorization of the Pediatric Rare Disease Priority Review Voucher Program. Most Favored Nation (MFN) models and international reference pricing, including GLOBE and GUARD
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B WORKING TABLE via LEAVITT PARTNERS, LLC
2026 · second_quarter · Q2
Improvements to the 340B drug discount program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SICKLE CELL DISEASE PARTNERSHIP via LEAVITT PARTNERS, LLC
2026 · second_quarter · Q2
Sickle cell disease focused legislation, federal funding, and federal programs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE DUAL ELIGIBLE COALITION via LEAVITT PARTNERS, LLC
2026 · second_quarter · Q2
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via LEAVITT PARTNERS, LLC
2026 · first_quarter · Q1
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2026 · first_quarter · Q1
Work with Congress and the Administration to ensure Medicaid coverage of genomic sequencing for children with suspected rare diseases, genetic disorders, and undiagnosed conditions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SAVE RARE TREATMENTS TASK FORCE via LEAVITT PARTNERS, LLC
2026 · first_quarter · Q1
Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases. Reauthorization of the Pediatric Rare Disease Priority Review Voucher Program. Most Favored Nation (MFN) models and international reference pricing, including GLOBE and GUARD
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B WORKING TABLE via LEAVITT PARTNERS, LLC
2026 · first_quarter · Q1
Improvements to the 340B drug discount program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SICKLE CELL DISEASE PARTNERSHIP via LEAVITT PARTNERS, LLC
2026 · first_quarter · Q1
Sickle cell disease focused legislation, federal funding, and federal programs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE DUAL ELIGIBLE COALITION via LEAVITT PARTNERS, LLC
2026 · first_quarter · Q1
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2025 · fourth_quarter · Q4
Work with Congress and the Administration to ensure Medicaid coverage of genomic sequencing for children with suspected rare diseases, genetic disorders, and undiagnosed conditions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SICKLE CELL DISEASE PARTNERSHIP via LEAVITT PARTNERS, LLC
2025 · fourth_quarter · Q4
Sickle cell disease focused legislation, federal funding, and federal programs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE DUAL ELIGIBLE COALITION via LEAVITT PARTNERS, LLC
2025 · fourth_quarter · Q4
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S.4264 Advancing Integration in Medicare and Medicaid Act -S.3630 The Supporting Care for Dual Eligibles Act -S.3950 DUALS Act of 2024
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
340B WORKING TABLE via LEAVITT PARTNERS, LLC
2025 · fourth_quarter · Q4
Improvements to the 340B drug discount program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAVE RARE TREATMENTS TASK FORCE via LEAVITT PARTNERS, LLC
2025 · fourth_quarter · Q4
Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases. Reauthorization of the Pediatric Rare Disease Priority Review Voucher Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2025 · third_quarter · Q3
Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SAVE RARE TREATMENTS TASK FORCE via LEAVITT PARTNERS, LLC
2025 · third_quarter · Q3
Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B WORKING TABLE via LEAVITT PARTNERS, LLC
2025 · third_quarter · Q3
Improvements to the 340B drug discount program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SICKLE CELL DISEASE PARTNERSHIP via LEAVITT PARTNERS, LLC
2025 · third_quarter · Q3
Sickle cell disease focused legislation, federal funding, and federal programs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE DUAL ELIGIBLE COALITION via LEAVITT PARTNERS, LLC
2025 · third_quarter · Q3
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2025 · second_quarter · Q2
Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SICKLE CELL DISEASE PARTNERSHIP via LEAVITT PARTNERS, LLC
2025 · second_quarter · Q2
Sickle cell disease focused legislation, federal funding, and federal programs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SAVE RARE TREATMENTS TASK FORCE via LEAVITT PARTNERS, LLC
2025 · second_quarter · Q2
Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B WORKING TABLE via LEAVITT PARTNERS, LLC
2025 · second_quarter · Q2
Improvements to the 340B drug discount program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE DUAL ELIGIBLE COALITION via LEAVITT PARTNERS, LLC
2025 · second_quarter · Q2
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2025 · first_quarter · Q1
Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SAVE RARE TREATMENTS TASK FORCE via LEAVITT PARTNERS, LLC
2025 · first_quarter · Q1
Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SICKLE CELL DISEASE PARTNERSHIP via LEAVITT PARTNERS, LLC
2025 · first_quarter · Q1
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
340B WORKING TABLE via LEAVITT PARTNERS, LLC
2025 · first_quarter · Q1
Improvements to the 340B drug discount program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE DUAL ELIGIBLE COALITION via LEAVITT PARTNERS, LLC
2025 · first_quarter · Q1
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SICKLE CELL DISEASE PARTNERSHIP via LEAVITT PARTNERS, LLC
2024 · fourth_quarter · Q4
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SAVE RARE TREATMENTS TASK FORCE via LEAVITT PARTNERS, LLC
2024 · fourth_quarter · Q4
Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE DUAL ELIGIBLE COALITION via LEAVITT PARTNERS, LLC
2024 · fourth_quarter · Q4
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2024 · fourth_quarter · Q4
Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
340B WORKING TABLE via LEAVITT PARTNERS, LLC
2024 · fourth_quarter · Q4
Improvements to the 340B drug discount program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2024 · third_quarter · 3A
Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2024 · second_quarter · 2A
Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2024 · third_quarter · Q3
Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SAVE RARE TREATMENTS TASK FORCE via LEAVITT PARTNERS, LLC
2024 · third_quarter · Q3
Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B WORKING TABLE via LEAVITT PARTNERS, LLC
2024 · third_quarter · Q3
Improvements to the 340B drug discount program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SICKLE CELL DISEASE PARTNERSHIP via LEAVITT PARTNERS, LLC
2024 · third_quarter · Q3
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE DUAL ELIGIBLE COALITION via LEAVITT PARTNERS, LLC
2024 · third_quarter · Q3
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2024 · second_quarter · RR
Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.
SAVE RARE TREATMENTS TASK FORCE via LEAVITT PARTNERS, LLC
2024 · second_quarter · Q2
Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SICKLE CELL DISEASE PARTNERSHIP via LEAVITT PARTNERS, LLC
2024 · second_quarter · Q2
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
340B WORKING TABLE via LEAVITT PARTNERS, LLC
2024 · second_quarter · Q2
Improvements to the 340B drug discount program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE DUAL ELIGIBLE COALITION via LEAVITT PARTNERS, LLC
2024 · second_quarter · Q2
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SICKLE CELL DISEASE PARTNERSHIP via LEAVITT PARTNERS, LLC
2024 · first_quarter · Q1
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SAVE RARE TREATMENTS TASK FORCE via LEAVITT PARTNERS, LLC
2024 · first_quarter · Q1
Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B WORKING TABLE via LEAVITT PARTNERS, LLC
2024 · first_quarter · Q1
Improvements to the 340B drug discount program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE DUAL ELIGIBLE COALITION via LEAVITT PARTNERS, LLC
2024 · first_quarter · Q1
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SAVE RARE TREATMENTS TASK FORCE via LEAVITT PARTNERS, LLC
2023 · fourth_quarter · Q4
Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B WORKING TABLE via LEAVITT PARTNERS, LLC
2023 · fourth_quarter · Q4
Improvements to the 340B drug discount program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SICKLE CELL DISEASE PARTNERSHIP via LEAVITT PARTNERS, LLC
2023 · fourth_quarter · Q4
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE DUAL ELIGIBLE COALITION via LEAVITT PARTNERS, LLC
2023 · fourth_quarter · Q4
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SAVE RARE TREATMENTS TASK FORCE via LEAVITT PARTNERS, LLC
2023 · fourth_quarter · RR
Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.
340B WORKING TABLE via LEAVITT PARTNERS, LLC
2023 · third_quarter · Q3
Improvements to the 340B drug discount program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SICKLE CELL DISEASE PARTNERSHIP via LEAVITT PARTNERS, LLC
2023 · third_quarter · Q3
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE DUAL ELIGIBLE COALITION via LEAVITT PARTNERS, LLC
2023 · third_quarter · Q3
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
340B WORKING TABLE via LEAVITT PARTNERS, LLC
2023 · second_quarter · Q2
Improvements to the 340B drug discount program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SICKLE CELL DISEASE PARTNERSHIP via LEAVITT PARTNERS, LLC
2023 · second_quarter · Q2
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COVID PATIENT RECOVERY ALLIANCE via LEAVITT PARTNERS, LLC
2023 · second_quarter · 2T
Federal polices related to developing national solutions that coordinate diverse data sources, inform the development of models of care, and ensure adequate payment for long-COVID patients, with a focus on the most vulnerable.
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
THE DUAL ELIGIBLE COALITION via LEAVITT PARTNERS, LLC
2023 · second_quarter · Q2
-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
340B WORKING TABLE via LEAVITT PARTNERS, LLC
2023 · second_quarter · RR
Improvements to the 340B drug discount program.
SICKLE CELL DISEASE PARTNERSHIP via LEAVITT PARTNERS, LLC
2023 · first_quarter · Q1
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE ENROLLMENT COALITION via LEAVITT PARTNERS, LLC
2023 · first_quarter · Q1
Federal polices related to Medicaid, CHIP, and health insurance that federal policymakers can adopt to improve enrollment data, systems, and processes to foster the enrollment of uninsured Americans under age 65 into existing health coverage plans and programs for which they are otherwise eligible.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE DUAL ELIGIBLE COALITION via LEAVITT PARTNERS, LLC
2023 · first_quarter · Q1
Issues related to dual eligible beneficiaries including: S.4635 - Comprehensive Care for Dual Eligible Individuals Act S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 S, 4264 Advancing Integration in Medicare and Medicaid Act S. 3630 The Supporting Care for Dual Eligibles Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SICKLE CELL DISEASE PARTNERSHIP via LEAVITT PARTNERS, LLC
2022 · fourth_quarter · Q4
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COVID PATIENT RECOVERY ALLIANCE via LEAVITT PARTNERS, LLC
2022 · fourth_quarter · Q4
Federal polices related to developing national solutions that coordinate diverse data sources, inform the development of models of care, and ensure adequate payment for long-COVID patients, with a focus on the most vulnerable.
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
THE ENROLLMENT COALITION via LEAVITT PARTNERS, LLC
2022 · fourth_quarter · Q4
Federal polices related to Medicaid, CHIP, and health insurance that federal policymakers can adopt to improve enrollment data, systems, and processes to foster the enrollment of uninsured Americans under age 65 into existing health coverage plans and programs for which they are otherwise eligible.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LUNDBECK PHARMACEUTICALS, LLC via LEAVITT PARTNERS, LLC
2022 · fourth_quarter · 4T
Issues related to the creation of a Neuroscience Center of Excellence at FDA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE DUAL ELIGIBLE COALITION via LEAVITT PARTNERS, LLC
2022 · fourth_quarter · Q4
Issues related to dual eligible beneficiaries including: S.4635 - Comprehensive Care for Dual Eligible Individuals Act S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 S, 4264 Advancing Integration in Medicare and Medicaid Act S. 3630 The Supporting Care for Dual Eligibles Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE DUAL ELIGIBLE COALITION via LEAVITT PARTNERS, LLC
2022 · third_quarter · 3A
Issues related to dual eligible beneficiaries including: S.4635 - Comprehensive Care for Dual Eligible Individuals Act S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 S, 4264 Advancing Integration in Medicare and Medicaid Act S. 3630 The Supporting Care for Dual Eligibles Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LUNDBECK PHARMACEUTICALS, LLC via LEAVITT PARTNERS, LLC
2022 · third_quarter · Q3
Issues related to the creation of a Neuroscience Center of Excellence at FDA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COVID PATIENT RECOVERY ALLIANCE via LEAVITT PARTNERS, LLC
2022 · third_quarter · Q3
Federal polices related to developing national solutions that coordinate diverse data sources, inform the development of models of care, and ensure adequate payment for long-COVID patients, with a focus on the most vulnerable.
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
THE ENROLLMENT COALITION via LEAVITT PARTNERS, LLC
2022 · third_quarter · Q3
Federal polices related to Medicaid, CHIP, and health insurance that federal policymakers can adopt to improve enrollment data, systems, and processes to foster the enrollment of uninsured Americans under age 65 into existing health coverage plans and programs for which they are otherwise eligible.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE DUAL ELIGIBLE COALITION via LEAVITT PARTNERS, LLC
2022 · third_quarter · Q3
Issues related to the Dual Eligible program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SICKLE CELL DISEASE PARTNERSHIP via LEAVITT PARTNERS, LLC
2022 · third_quarter · Q3
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SICKLE CELL DISEASE PARTNERSHIP via LEAVITT PARTNERS, LLC
2022 · second_quarter · 2A
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE ENROLLMENT COALITION via LEAVITT PARTNERS, LLC
2022 · second_quarter · 2A
Federal polices related to Medicaid, CHIP, and health insurance that federal policymakers can adopt to improve enrollment data, systems, and processes to foster the enrollment of uninsured Americans under age 65 into existing health coverage plans and programs for which they are otherwise eligible.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COVID PATIENT RECOVERY ALLIANCE via LEAVITT PARTNERS, LLC
2022 · second_quarter · 2A
Federal polices related to developing national solutions that coordinate diverse data sources, inform the development of models of care, and ensure adequate payment for long-COVID patients, with a focus on the most vulnerable.
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
THE ENROLLMENT COALITION via LEAVITT PARTNERS, LLC
2022 · second_quarter · Q2
Federal polices related to Medicaid, CHIP, and health insurance that federal policymakers can adopt to improve enrollment data, systems, and processes to foster the enrollment of uninsured Americans under age 65 into existing health coverage plans and programs for which they are otherwise eligible.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COVID PATIENT RECOVERY ALLIANCE via LEAVITT PARTNERS, LLC
2022 · second_quarter · Q2
Federal polices related to developing national solutions that coordinate diverse data sources, inform the development of models of care, and ensure adequate payment for long-COVID patients, with a focus on the most vulnerable.
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
LUNDBECK PHARMACEUTICALS, LLC via LEAVITT PARTNERS, LLC
2022 · second_quarter · Q2
Issues related to the creation of a Neuroscience Center of Excellence at FDA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE DUAL ELIGIBLE COALITION via LEAVITT PARTNERS, LLC
2022 · second_quarter · Q2
Issues related to the Dual Eligible program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SICKLE CELL DISEASE PARTNERSHIP via LEAVITT PARTNERS, LLC
2022 · second_quarter · RR
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.
COVID PATIENT RECOVERY ALLIANCE via LEAVITT PARTNERS, LLC
2022 · first_quarter · Q1
Federal polices related to developing national solutions that coordinate diverse data sources, inform the development of models of care, and ensure adequate payment for long-COVID patients, with a focus on the most vulnerable.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE ENROLLMENT COALITION via LEAVITT PARTNERS, LLC
2022 · first_quarter · Q1
Federal polices related to Medicaid, CHIP, and health insurance that federal policymakers can adopt to improve enrollment data, systems, and processes to foster the enrollment of uninsured Americans under age 65 into existing health coverage plans and programs for which they are otherwise eligible.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LUNDBECK PHARMACEUTICALS, LLC via LEAVITT PARTNERS, LLC
2022 · first_quarter · Q1
Issues related to the creation of a Neuroscience Center of Excellence at FDA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE DUAL ELIGIBLE COALITION via LEAVITT PARTNERS, LLC
2022 · first_quarter · Q1
Issues related to the Dual Eligible program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE ENROLLMENT COALITION via LEAVITT PARTNERS, LLC
2021 · fourth_quarter · 4A
Federal polices related to Medicaid, CHIP, and health insurance that federal policymakers can adopt to improve enrollment data, systems, and processes to foster the enrollment of uninsured Americans under age 65 into existing health coverage plans and programs for which they are otherwise eligible.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE